NDAORALTABLET
Approved
Jul 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KEMADRIN (procyclidine hydrochloride) is an oral anticholinergic agent approved in 1955 for managing extrapyramidal side effects and parkinsonism. It works by blocking acetylcholine receptors in the central nervous system to reduce involuntary movement and tremor. This is a legacy small-molecule therapeutic with a well-established but narrow clinical niche.
LOE Approaching
As an approaching loss-of-exclusivity product with minimal linked roles, this brand operates with a skeleton team focused on retention and cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KEMADRIN offers minimal career development due to its mature lifecycle stage and approaching loss of exclusivity; roles are primarily focused on revenue retention and market access rather than innovation or expansion. Professionals should view this assignment as a specialized niche role with limited upward mobility or external market demand.
Brand ManagerField Sales Representative
Worked on KEMADRIN at Monarch Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.